AbbVie Out $5.8 Billion After Scrapping Rova-T Program - BioSpace

AbbVie Out $5.8 Billion After Scrapping Rova-T Program  BioSpace

AbbVie announced that the Phase III MERU trial evaluating Rova-T as first-line maintenance therapy for advanced small-cell lung cancer, failed to demonstrate ...



Comments

Popular posts from this blog

A Review of the Etiology and Epidemiology of Bladder Cancer: All ...

Oncology: The disease, dynamics & challenges of market research

Division of Continuing Professional Development